February 10, 2023 – Thanks Mergermarket (an ION group company) for your cover of our exciting news “GlyTherix seeks USD 10m in pre-IPO funding ahead of planned listing in 2024 – CEO”.
Our Phase 1b study will be a pivotal event for the company as we develop a vital new cancer theranostic drug.
Read the full article here.